DRIVE-AB Stakeholder Meeting: SME Feedback on Innovation Incentives
Antibacterial drug innovation is receiving significant political attention following the UK government’s response to the increasing antibiotic resistance problem by commissioning the AMR Review, including among the G7 and G20 countries, the European Commission, the World Health Organization, the OECD and at the United Nations General Assembly. There is growing interest at the highest political level in various incentives and new economic models to stimulate innovation in the antibiotic field.
In preparing and refining a selection of incentives, the DRIVE-AB consortium views the engagement of key stakeholders, such as SMEs operating in antibiotic R&D, as particularly important. The purpose of this meeting is accordingly to receive feedback from invited SME representatives on two main aspects of the proposed economic models and incentives:
- Their overall structure and combination across the antibiotic R&D pipeline
- The details of single specific models and incentives
The Centre on Global Health Security at Chatham House forms part of the DRIVE-AB consortium, which working under the European Commission, brings together leading research institutions to develop new business models for antibiotics development.
Attendance at this event is by invitation only.